Servier beefs up in cancer, buying Agios’ oncology business for $1.8bn
pharmaphorum
DECEMBER 23, 2020
This year it’s also doubled down on an alliance with off-the-shelf CAR-T specialist Cellectis , and bought Danish cancer biotech Symphogen. The Agios deal comes just a day after Servier announced a strategic alliance with Celsius Therapeutics to find new drug targets for colorectal cancer.
Let's personalize your content